The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of avß3 and avß5

Julie C. Crockett, Norbert Schütze, Denise Tosh, Susanne Jatzke, Angela Duthie, Franz Jakob, Michael J. Rogers

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including alpha(v)beta(3) and alpha(v)beta(5). Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, alpha(v)beta(3)-positive, or tartrate-resistant acid phosphatasepositive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast phenotypic markers tartrate-resistant acid phosphatase, matrix metalloproteinase-9, calcitonin receptor, and cathepsin K. However, CYR61 did not affect the formation of multinucleated osteoclasts when added to osteoclast precursors prior to fusion or affect the number or resorptive activity of osteoclasts cultured on dentine discs, indicating that CYR61 affects early osteoclast precursors but not mature osteoclasts. CYR61 did not affect receptor activator of nuclear factor-kappa B (RANK) ligand-induced phosphorylation of p38 or ERK1/2 in human macrophages and did not affect RANK ligand-induced activation of nuclear factor-kappa B, indicating that CYR61 does not appear to inhibit osteoclastogenesis by affecting RANK signaling. Furthermore, a mutant form of CYR61 defective in binding to alpha(v)beta(3) also inhibited osteoclastogenesis, and CYR61 inhibited osteoclastogenesis similarly in cultures of mouse wild-type or beta(-/)(5)-macrophages. Thus, CYR61 does not appear to inhibit osteoclast formation by interacting with alpha(v)beta(3) or alpha(v)beta(5). These observations demonstrate that CYR61 is a hitherto unrecognized inhibitor of osteoclast formation, although the exact mechanism of inhibition remains to be determined. Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling.

Original languageEnglish
Pages (from-to)5761-5768
Number of pages8
JournalEndocrinology
Volume148
Issue number12
Early online date6 Sep 2007
DOIs
Publication statusPublished - 1 Dec 2007

Keywords

  • immediate-early gene
  • angiogenic factor
  • breast-cancer
  • integrin alpha(V)beta(3)
  • vitronectin receptor
  • endothelial-cells
  • beta-3 integrin
  • growth-factors
  • CCN family
  • expression

Cite this

Crockett, J. C., Schütze, N., Tosh, D., Jatzke, S., Duthie, A., Jakob, F., & Rogers, M. J. (2007). The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of avß3 and avß5. Endocrinology, 148(12), 5761-5768. https://doi.org/10.1210/en.2007-0473

The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of avß3 and avß5. / Crockett, Julie C.; Schütze, Norbert; Tosh, Denise; Jatzke, Susanne; Duthie, Angela; Jakob, Franz; Rogers, Michael J.

In: Endocrinology, Vol. 148, No. 12, 01.12.2007, p. 5761-5768.

Research output: Contribution to journalArticle

Crockett, JC, Schütze, N, Tosh, D, Jatzke, S, Duthie, A, Jakob, F & Rogers, MJ 2007, 'The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of avß3 and avß5' Endocrinology, vol. 148, no. 12, pp. 5761-5768. https://doi.org/10.1210/en.2007-0473
Crockett, Julie C. ; Schütze, Norbert ; Tosh, Denise ; Jatzke, Susanne ; Duthie, Angela ; Jakob, Franz ; Rogers, Michael J. / The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of avß3 and avß5. In: Endocrinology. 2007 ; Vol. 148, No. 12. pp. 5761-5768.
@article{52adc89c5352414d9a1bc49d5ed5d2c1,
title = "The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of av{\ss}3 and av{\ss}5",
abstract = "Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including alpha(v)beta(3) and alpha(v)beta(5). Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, alpha(v)beta(3)-positive, or tartrate-resistant acid phosphatasepositive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast phenotypic markers tartrate-resistant acid phosphatase, matrix metalloproteinase-9, calcitonin receptor, and cathepsin K. However, CYR61 did not affect the formation of multinucleated osteoclasts when added to osteoclast precursors prior to fusion or affect the number or resorptive activity of osteoclasts cultured on dentine discs, indicating that CYR61 affects early osteoclast precursors but not mature osteoclasts. CYR61 did not affect receptor activator of nuclear factor-kappa B (RANK) ligand-induced phosphorylation of p38 or ERK1/2 in human macrophages and did not affect RANK ligand-induced activation of nuclear factor-kappa B, indicating that CYR61 does not appear to inhibit osteoclastogenesis by affecting RANK signaling. Furthermore, a mutant form of CYR61 defective in binding to alpha(v)beta(3) also inhibited osteoclastogenesis, and CYR61 inhibited osteoclastogenesis similarly in cultures of mouse wild-type or beta(-/)(5)-macrophages. Thus, CYR61 does not appear to inhibit osteoclast formation by interacting with alpha(v)beta(3) or alpha(v)beta(5). These observations demonstrate that CYR61 is a hitherto unrecognized inhibitor of osteoclast formation, although the exact mechanism of inhibition remains to be determined. Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling.",
keywords = "immediate-early gene, angiogenic factor, breast-cancer, integrin alpha(V)beta(3), vitronectin receptor, endothelial-cells, beta-3 integrin, growth-factors, CCN family, expression",
author = "Crockett, {Julie C.} and Norbert Sch{\"u}tze and Denise Tosh and Susanne Jatzke and Angela Duthie and Franz Jakob and Rogers, {Michael J.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1210/en.2007-0473",
language = "English",
volume = "148",
pages = "5761--5768",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of avß3 and avß5

AU - Crockett, Julie C.

AU - Schütze, Norbert

AU - Tosh, Denise

AU - Jatzke, Susanne

AU - Duthie, Angela

AU - Jakob, Franz

AU - Rogers, Michael J.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including alpha(v)beta(3) and alpha(v)beta(5). Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, alpha(v)beta(3)-positive, or tartrate-resistant acid phosphatasepositive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast phenotypic markers tartrate-resistant acid phosphatase, matrix metalloproteinase-9, calcitonin receptor, and cathepsin K. However, CYR61 did not affect the formation of multinucleated osteoclasts when added to osteoclast precursors prior to fusion or affect the number or resorptive activity of osteoclasts cultured on dentine discs, indicating that CYR61 affects early osteoclast precursors but not mature osteoclasts. CYR61 did not affect receptor activator of nuclear factor-kappa B (RANK) ligand-induced phosphorylation of p38 or ERK1/2 in human macrophages and did not affect RANK ligand-induced activation of nuclear factor-kappa B, indicating that CYR61 does not appear to inhibit osteoclastogenesis by affecting RANK signaling. Furthermore, a mutant form of CYR61 defective in binding to alpha(v)beta(3) also inhibited osteoclastogenesis, and CYR61 inhibited osteoclastogenesis similarly in cultures of mouse wild-type or beta(-/)(5)-macrophages. Thus, CYR61 does not appear to inhibit osteoclast formation by interacting with alpha(v)beta(3) or alpha(v)beta(5). These observations demonstrate that CYR61 is a hitherto unrecognized inhibitor of osteoclast formation, although the exact mechanism of inhibition remains to be determined. Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling.

AB - Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including alpha(v)beta(3) and alpha(v)beta(5). Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, alpha(v)beta(3)-positive, or tartrate-resistant acid phosphatasepositive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast phenotypic markers tartrate-resistant acid phosphatase, matrix metalloproteinase-9, calcitonin receptor, and cathepsin K. However, CYR61 did not affect the formation of multinucleated osteoclasts when added to osteoclast precursors prior to fusion or affect the number or resorptive activity of osteoclasts cultured on dentine discs, indicating that CYR61 affects early osteoclast precursors but not mature osteoclasts. CYR61 did not affect receptor activator of nuclear factor-kappa B (RANK) ligand-induced phosphorylation of p38 or ERK1/2 in human macrophages and did not affect RANK ligand-induced activation of nuclear factor-kappa B, indicating that CYR61 does not appear to inhibit osteoclastogenesis by affecting RANK signaling. Furthermore, a mutant form of CYR61 defective in binding to alpha(v)beta(3) also inhibited osteoclastogenesis, and CYR61 inhibited osteoclastogenesis similarly in cultures of mouse wild-type or beta(-/)(5)-macrophages. Thus, CYR61 does not appear to inhibit osteoclast formation by interacting with alpha(v)beta(3) or alpha(v)beta(5). These observations demonstrate that CYR61 is a hitherto unrecognized inhibitor of osteoclast formation, although the exact mechanism of inhibition remains to be determined. Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling.

KW - immediate-early gene

KW - angiogenic factor

KW - breast-cancer

KW - integrin alpha(V)beta(3)

KW - vitronectin receptor

KW - endothelial-cells

KW - beta-3 integrin

KW - growth-factors

KW - CCN family

KW - expression

U2 - 10.1210/en.2007-0473

DO - 10.1210/en.2007-0473

M3 - Article

VL - 148

SP - 5761

EP - 5768

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 12

ER -